Role of Single-Pill Combination Therapy in Optimizing Blood Pressure Control in High-Risk Hypertension Patients and Management of Treatment-Related Adverse Events
Article first published online: 13 AUG 2012
© 2012 Wiley Periodicals, Inc.
The Journal of Clinical Hypertension
Volume 14, Issue 10, pages 718–726, October 2012
How to Cite
Abdellatif, A. A. (2012), Role of Single-Pill Combination Therapy in Optimizing Blood Pressure Control in High-Risk Hypertension Patients and Management of Treatment-Related Adverse Events. The Journal of Clinical Hypertension, 14: 718–726. doi: 10.1111/j.1751-7176.2012.00696.x
- Issue published online: 2 OCT 2012
- Article first published online: 13 AUG 2012
- Manuscript received: February 28, 2012; revised: May 16, 2012; accepted: July 4, 2012
J Clin Hypertens (Greenwich). 2012;14:718–726. ©2012 Wiley Periodicals, Inc.
Renin-angiotensin-aldosterone system (RAAS) inhibitors in combination with other antihypertensive drugs (eg, calcium channel blockers [CCBs] and/or diuretics) are a preferred treatment option for managing uncontrolled hypertension in high-risk patients with chronic kidney disease (CKD), diabetes, or heart failure because RAAS inhibitors provide cardiorenal benefits in addition to lowering blood pressure (BP). However, when prescribing antihypertensive therapies to high-risk patients, physicians must be aware of the risks of treatment-related adverse events of hyperkalemia and peripheral edema associated with RAAS inhibitors and CCBs, respectively. This review discusses the use of single-pill combination antihypertensive therapy to optimize BP control in high-risk patients with CKD, diabetes, and/or heart failure and provides strategies for preventing and managing hyperkalemia and peripheral edema in this group. Single-pill combination therapy can utilize different classes of antihypertensive drugs to reduce BP while mitigating the risks of treatment-related adverse events, reducing pill burden, lowering medical cost, and improving patient compliance.